Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR: Incidence, Diagnosis, Predictors, and Management
Bismee, Nadera N. , Javadi, Niloofar , Khedr, Ahmed E. , Omar, Fatma, Awad, Kamal , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Pereyra, Milagros , Bcharah, George , Farina, Juan M. , Arsanjani, Reza , Khedr, Ahmed , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal , Omar, Fatma, Sell‐Dottin, Kristen

Journal of Cardiovascular Development and Disease | December 2, 2024 | Volume: 11 | Issue: 12 | Pages: 384

10.3390/jcdd11120384 | PMID 39728274 Get It

Bioprosthetic aortic valve degeneration (BAVD) is a significant clinical concern following both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). The increasing use of bioprosthetic valves in aortic valve replacement in younger patients and the subsequent rise in cases of BAVD are acknowledged in this review which aims to provide a comprehensive overview of the incidence, diagnosis, predictors, and management of BAVD. Based on a thorough review of the existing literature, this article provides an updated overview of the biological mechanisms underlying valve degeneration, including calcification, structural deterioration, and inflammatory processes and addresses the various risk factors contributing to BAVD, such as patient demographics, comorbidities, and procedural variables. The difficulties in early detection and accurate diagnosis of BAVD are discussed with an emphasis on the need for improved imaging techniques. The incidence and progression of BAVD in patients undergoing TAVR versus SAVR are compared, providing insights into the differences and similarities between the two procedures and procedural impacts on valve longevity. The current strategies for managing BAVD, including re-intervention options of redo surgery and valve-in-valve TAVR, along with emerging treatments are discussed. The controversies in the existing literature are highlighted to offer directions for future investigations to enhance the understanding and management of BAVD.
Comparison of Culturing Methods of Primary Vaginal Fibroblasts
Parsons, Tammee M., Perkerson, Ralph B., Glembotski, C C, Zenhausern, Frédéric , Gurtner, Geoffrey C. , Alperin, Marianna , Kanekiyo, Takahisa , Cardenas-Trowers, Olivia O. , Zhao, Jing

Urogynecology | December 2, 2024 | Volume: 31 | Issue: 11 | Pages: 1054-1061

10.1097/spv.0000000000001612 | PMID 39621417 Get It

Importance Vaginal fibroblast function is altered in people with pelvic organ prolapse. Thus, it is important to study vaginal fibroblasts to better understand the pathophysiology of prolapse. Objective This study aimed to compare 3 culturing methods of primary vaginal fibroblasts. Study Design This was an in vitro study. Patients who were undergoing surgery for vaginal prolapse were recruited. Excess vaginal epithelial tissue that would have otherwise been discarded was collected. The vaginal fibroblasts from each participant were cultured via (1) 3-hour digest, (2) coverslip, and (3) gelatin-coat methods. Differences in the efficiency of cell isolation, expression of known fibroblast-associated genes, and cellular function were compared between the 3 methods using one-way analysis of variance and Tukey test for post hoc pairwise comparisons ( P < 0.05). Results Five patients with pelvic organ prolapse were recruited. Fibroblasts cultured via the 3-hour digest method became confluent within 3–5 days in a 100-mm dish compared to 2–3 weeks in a 6-well dish for the coverslip and gelatin-coat methods. Cells from all culture methods expressed similar amounts of vimentin and α smooth muscle actin. There were no significant differences in morphology; gene expression levels of MMP1 , MMP2 , ACTA2 , COL1A1 , COL3A1 , and LOXL1 on qPCR; cell viability; proliferation; and migration between the 3 culturing methods. Conclusion Culturing primary vaginal fibroblasts via the 3-hour digest, coverslip, and gelatin-coat methods similarly resulted in reliable primary vaginal fibroblast growth and function.
Longitudinal Study of Patients with Connective Tissue Disease–Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab
Li, Yan , Mumtaz, Sehreen , Baig, Hassan , Mira‐Avendano, Isabel , Wang, Benjamin , Rojas, Carlos A. , Stowell, Justin T. , Lesser, Elizabeth R. , Borkar, Shalmali R. , Majithia, Vikas , Abril, Andy , Baig, Hassan Z , Majithia, Vikas , Mumtaz, Sehreen

Diagnostics | December 2, 2024 | Volume: 14 | Issue: 23 | Pages: 2702

10.3390/diagnostics14232702 | PMID 39682611 Get It

Background/Objective: To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Methods: Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up. Results: Forty-seven patients with CTD-ILD, treated with MMF, RTX, or both, were included. Patients on combined MMF and RTX had worse PFT outcomes at baseline compared with patients on monotherapy. Substantial improvement was observed among all PFT outcomes from baseline to 12 months, regardless of medication dosage or therapy plans. The diffusing capacity of the lungs for carbon monoxide (DLCO) worsened by an average of 7.21 mL/(min*mmHg) (95% CI, 4.08–10.33; p < 0.001) among patients on RTX compared to combined therapy. Patients on higher doses of MMF at baseline experienced an average increase of 0.93 (95% CI, 0.04–1.82) units in DLCO from baseline to 6 months (p = 0.04) and a 2.79% (95% CI, 0.61–4.97%) increase in DLCO from 6 to 12 months (p = 0.02) within patients on concurrent RTX at 6-month follow-up. Conclusions: The treatment of CTD-ILD with MMF and/or RTX was associated with overall improvement in PFT outcomes. Combined therapy resulted in significant improvements in DLCO compared with monotherapy. Higher doses of MMF also provided greater improvements in DLCO.
Accuracy of Fecal Polymerase Chain Reaction Testing in Clarithromycin-Resistant Helicobacter Pylori: A Systematic Review and Meta-Analysis
Qady, Ahmed Al , Salih, Mohamed, Ali, Marriam, Menakuru, Sasmith, Nayar, Kapil Dev, Wang, Zhen , Bi, Yan , Al Qady, Ahmed , Aldhaleei, Wafa, Harris, Dana, Aldhaleei, Wafa Ali , Nayar, Kapil Dev, Stancampiano, Fernando F. , Harris, Dana M.

Clinical and Translational Gastroenterology | December 2, 2024 | Volume: 16 | Issue: 2 | Pages: e00792

10.14309/ctg.0000000000000792 | PMID 39620581 Get It

INTRODUCTION: The increasing prevalence of clarithromycin (CLA)-resistant Helicobacter pylori (H. pylori) strains poses a significant challenge in the management of H. pylori infections. This systematic review and meta-analysis investigates the diagnostic accuracy of polymerase chain reaction (PCR) in identifying CLA-resistant H. pylori strains in stool. METHODS: A comprehensive literature search was conducted using PubMed, Embase, and Cochrane databases from database inception to April 30, 2023. Eligible studies evaluated the effectiveness of PCR stool tests in detecting CLA-resistant H. pylori strains in adults (>18-year-old). Studies of pediatric populations, alternative methods to PCR or stool samples, and reference tests other than gastric biopsy were excluded. The bivariate random-effects model was used to pool diagnostic accuracy from the included studies. RESULTS: The analysis of 11 prospective diagnostic studies with a total of 866 patients showed a pooled sensitivity of 0.97 (95% CI: 0.9–0.99) and a pooled specificity of 0.98 (95% CI: 0.81–1.00). Subgroup analysis based on the used technique demonstrated consistent findings without notable variations. The diagnostic odds ratio was calculated at 1843.92 (95% CI: 134.28–25,321.3). The positive likelihood ratio was determined as 51.02 (95% CI: 4.61–564.5), while the negative likelihood ratio was found to be 0.03 (95% CI: 0.01–0.1). DISCUSSION: PCR testing for clarithromycin-resistant H. pylori was highly sensitive and specific across studies with proven reliability in clinical practice, particularly in outpatient settings. Their implementation offers cost-effectiveness and the potential for tailored treatment strategies, holding promise for improved patient outcomes.
RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity
Jung, Seong-Mook , Park, Young Chae, Seo, Eun Suk, Kim, Cheol Gyun , Kim, Taewoo , Yun, Cheol‐Heui , Shim, Byoung-Shik, Cheon, In Su , Son, Young Min , Yun, Cheol-Heui , Kim, Soo Ji , Seo, Eun Sang, Lee, Sumin , Cho, Eunjin, Chang, Jun , Shim, Byoung-Shik

Vaccines | December 2, 2024 | Volume: 12 | Issue: 12 | Pages: 1354

10.3390/vaccines12121354 | PMID 39772016 Get It

Background/Objectives: Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (TRM) cells and tissue-resident memory B (BRM) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. Methods: We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. Results: Consequently, antigen-specific CD8+ TRM cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69+ IgG+ BRM cells were significantly increased in lung tissues in the RSV-PST group. Conclusions: The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.
From the Editor-in-Chief’s Desk: Keeping Our Eyes on The Ball and a Call for Discontinuation Research
Croarkin, Paul E.

Journal of Child and Adolescent Psychopharmacology | December 2, 2024 | Volume: 35 | Issue: 1 | Pages: 1-2

10.1089/cap.2024.0137 | PMID 39618236 Get It

Follow the LINE: A novel case of dilated cardiomyopathy caused by a LINE-1 insertion in the TTN gene
Ding, Qiliang , Fine, Jenna, Hoffman, Frank T, Kluge, Michelle L. , Kuennen, Rhonda K., Thieke, Sarah, Hoppman, Nicole L., Marcou, Cherisse A. , Rowsey, Ross, Thorland, Erik C., Baudhuin, Linnea M. , Moyer, Ann M. , Buglioni, Alessia , Thieke, Sarah M, Rowsey, Ross A, Fine, Jenna

American Journal of Clinical Pathology | December 1, 2024 | Volume: 163 | Issue: 4 | Pages: 511-515

10.1093/ajcp/aqae170 | PMID 39928391 Get It

Abstract Objectives Protein-truncating variants in the TTN gene are a well-established cause of dilated cardiomyopathy (DCM). We report a novel case of DCM caused by a mobile element insertion (MEI) in TTN, through which we highlight the key features of MEIs in next-generation sequencing data. Because of the rarity of MEIs, the next-generation sequencing data features associated with these events may be mistaken as noise, potentially leading to missed diagnoses. Methods Next-generation sequencing gene panel testing for DCM was performed on a 17-year-old male patient presenting with severe left ventricular dilatation and systolic dysfunction. Manta was used for structural variant detection, followed by manual review of NGS data for potential structural variants. Results Manta detected a potential insertion in TTN. Manual review identified hallmark features consistent with a LINE-1 MEI. This finding was orthogonally confirmed by long-range polymerase chain reaction and gel electrophoresis, which indicated an insertion of approximately 4 to 5 kilobase pairs. The insertion disrupted the reading frame of TTN within an A-band exon, resulting in protein truncation that was classified as likely pathogenic. Conclusions This case expands the mutational spectrum of TTN protein-truncating variants. It also underscores the importance of recognizing rarer types of pathogenic variants (eg, MEIs) to produce accurate genetic diagnostics.
35 Hardwiring psychological safety as the foundation for a successful quality and safety program
Hannafin, Cathy, Ponce, Lisa , Bowman, Andrew W. , Flug, Jonathan A.

Oral Presentation (OP) Abstracts | December 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: A24.1-A24

10.1136/bmjoq-2024-ihi.35 Get It

Robotic carotid artery stenting: a multicenter, propensity score–matched analysis of clinical outcomes and cost-effectiveness
Patel, Shray , Scott, Kyle, Abbas, Rawad , Fuleihan, Antony A. , Sivaganesan, Ahilan, Tjoumakaris, Stavropoula I., Rosenwasser, Robert H. , Srinivasan, Visish M. , Burkhardt, Jan‐Karl , Burkhardt, Jan‐Karl , Roy, Joanna M. , Musmar, Basel , Sarikonda, Advith , Scott, Kyle, Tjoumakaris, Stavropoula , Gooch, Michael Reid , Jabbour, Pascal

Neurosurgical Focus | December 1, 2024 | Volume: 57 | Issue: 6 | Pages: E10

10.3171/2024.9.focus24479 | PMID 39616641 Get It

OBJECTIVE Preclinical studies suggest that robotic carotid artery stenting (CAS) could be superior to manual CAS. However, very limited comparative data exist for patients who have undergone robotic versus manual CAS. In addition, no data exist comparing the costs of manual and robotic CAS. METHODS All robotic CAS cases at two academic neurosurgery centers were retrospectively reviewed and 1:1 propensity matched with manual CAS cases. Personnel costs, supply costs, and total procedure costs were collected in collaboration with hospital administration by using time-driven activity-based cost analysis. RESULTS A total of 24 robotic CAS operations were performed between 2019 and 2023. Comorbidities and baseline procedural characteristics were well matched between robotic and manual cases. Unplanned manual conversion was observed in only 1 robotic case (4.2%). Robotic CAS complications and outcomes were comparable to manual. Robotic CAS was associated with a significantly increased fluoroscopy time (29.0 vs 19.2 minutes; p < 0.001). Robotic procedure time (88.9 ± 18.2 minutes) was significantly (p = 0.003) longer than manual time (68.72 ± 22.4 minutes). Health personnel costs ($1589.71 ± $176.92 vs $1375.99 ± $233.39, p = 0.005); supply costs ($3918.25 ± $421.20 vs $2152.74 ± $1030.26, p < 0.001); and total procedure costs ($5306.11 ± $608.95 vs $3437.56 ± $1165.67, p < 0.001) were greater for robotic CAS. CONCLUSIONS In the first multicenter study and largest sample to date, the authors show that robotic CAS, with a low rate of procedural failure and postoperative complications, is safe and feasible. In addition, robotic CAS achieves comparable clinical outcomes to manual CAS. Robotic CAS was associated with increased fluoroscopy time, but fluoroscopy time decreased as operators gained familiarity with the CorPath GRX system. Robotic CAS was associated with a greater procedural cost, which was driven by greater personnel and supply costs. Robotic CAS failed to show superiority to manual CAS. These findings set a foundation for randomized controlled trials of robotic CAS, and also highlight the need for further studies to optimize robotic CAS and reduce its associated costs.
Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, Alan H. , Beltran, Himisha , Hussain, Maha , Armstrong, Andrew J. , Calais, Jérémie , Dorff, Tanya B. , Gomella, Leonard G. , Higano, Celestia, Morris, David S. , Petrylak, Daniel P. , Reiter, Robert E. , Ryan, Charles J. , Sellinger, Scott B., Srinivas, Sandy, Taplin, Mary‐Ellen , Zhang, Tian , McKay, Rana R. , Koo, Phillip J. , Crawford, E. David , Armstrong, Andrew J , Dorff, Tanya , Morris, Michael J , Spratt, Daniel E , Tagawa, Scott T , Zhang, Tian , Bryce, Alan H , Hussain, Maha H A , Calais, Jeremie , Agarwal, Neeraj, Sartor, Oliver , Shore, Neal D. , Antonarakis, Emmanuel S. , Carducci, Michael A. , Efstathiou, Jason A. , Gleave, Martin , Higano, Celestia S. , Hope, Thomas A. , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, David S., Morris, Michael J. , Rettig, Matthew B. , Spratt, Daniel E. , Tagawa, Scott T. , Yu, Evan Y.

Cancer | December 1, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35612 | PMID 39616467 Get It

AbstractCurrent US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day‐to‐day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US‐focused expert clinical decision‐making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration‐sensitive prostate cancer; poly [ADP‐ribose] polymerase inhibitors; prostate‐specific membrane antigen radioligand therapy; and metastatic, castration‐resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.